Bonus Biogroup Equity 2024

Bonus Biogroup Aktienanalyse

What does Bonus Biogroup do?

The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Bonus Biogroup's Equity

Bonus Biogroup's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bonus Biogroup's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bonus Biogroup's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bonus Biogroup's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bonus Biogroup’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bonus Biogroup stock

What is the equity of Bonus Biogroup this year?

Bonus Biogroup has equity of 56.39 M ILS this year.

What was the equity of Bonus Biogroup compared to the previous year?

The equity of Bonus Biogroup has increased/decreased by -33.21% decreased compared to the previous year.

What impact does a high equity have on investors of Bonus Biogroup?

A high equity is advantageous for investors of Bonus Biogroup as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Bonus Biogroup?

A low equity can be a risk for investors of Bonus Biogroup, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Bonus Biogroup affect the company?

An increase in equity of Bonus Biogroup can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Bonus Biogroup affect the company?

A reduction in equity of Bonus Biogroup can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Bonus Biogroup?

Some factors that can affect the equity of Bonus Biogroup include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Bonus Biogroup so important for investors?

The equity of Bonus Biogroup is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Bonus Biogroup take to change the equity?

To change equity, Bonus Biogroup can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Bonus Biogroup pay?

Over the past 12 months, Bonus Biogroup paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bonus Biogroup is expected to pay a dividend of 0 ILS.

What is the dividend yield of Bonus Biogroup?

The current dividend yield of Bonus Biogroup is .

When does Bonus Biogroup pay dividends?

Bonus Biogroup pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bonus Biogroup?

Bonus Biogroup paid dividends every year for the past 0 years.

What is the dividend of Bonus Biogroup?

For the upcoming 12 months, dividends amounting to 0 ILS are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bonus Biogroup located?

Bonus Biogroup is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bonus Biogroup kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bonus Biogroup from 12/5/2024 amounting to 0 ILS, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did Bonus Biogroup pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of Bonus Biogroup in the year 2023?

In the year 2023, Bonus Biogroup distributed 0 ILS as dividends.

In which currency does Bonus Biogroup pay out the dividend?

The dividends of Bonus Biogroup are distributed in ILS.